Key result
Combined WHO-5, ASS-2, and MDI-2 matches HADS for clinical anxiety and depression screening.
Why the study?
To evaluate whether combining WHO-5, ASS-2, and MDI-2 can replace HADS for screening anxiety and depression in cardiac patients and generate crosswalks for clinical practice.
Can a combination of WHO-5, ASS-2, and MDI-2 replace HADS as a screening tool for anxiety and depression in cardiac patients?
Cross-Sectional (n=4,346)
Can a combination of WHO-5, ASS-2, and MDI-2 replace HADS as a screening tool for anxiety and depression in cardiac patients?
Crosswalks between WHO-5/ASS-2/MDI-2 and HADS can be feasibly used to screen cardiac patients for anxiety and depression in clinical practice.
Answers are grounded in this paper and cite their sources.
May support crosswalk-based screening in cardiac patients; leaves open prospective validation before replacing HADS.
AIMS: The aim of this study was to evaluate if a combination of World Health Organization-5 (WHO-5), Anxiety Symptom Scale-2 (ASS-2), and Major Depression Inventory-2 (MDI-2) can replace the Hospital Anxiety and Depression Scale (HADS) as screening tool for anxiety and depression in cardiac patients across diagnoses and whether it is feasible to generate crosswalks (translation tables) for use in clinical practice. METHODS AND RESULTS: We used data from the Danish 'Life with a heart disease' survey, in which 10 000 patients with a hospital contact and discharge diagnosis of ischaemic heart disease, heart failure, heart valve disease, or atrial fibrillation in 2018 were invited. Potential participants received an electronic questionnaire including 51 questions on health, well-being, and evaluation of the health care system. Crosswalks between WHO-5/ASS-2 and HADS anxiety dimension (HADS-A) and between WHO-5/MDI-2 and HADS depression dimension (HADS-D) were generated and tested using item response theory (IRT). A total of 4346 patients responded to HADS, WHO-5, ASS-2, and MDI-2. Model fit of the bi-factor IRT models illustrated appropriateness of a bi-factor structure and thus of essential uni-dimensionality [root mean square error of approximation (RMSEA) (P value) range 0.000-0.053 (0.0099-0.7529) for anxiety and 0.033-0.061 (0.0168-0.2233) for depression]. A combination of WHO-5 and ASS-2 measured the same trait as HADS-A, and a combination of WHO-5 and MDI-2 measured the same trait as HADS-D. Consequently, crosswalks (translation tables) were generated. CONCLUSIONS: Our study shows that it is feasible to use crosswalks between HADS-A and WHO-5/ASS-2 and HADS-D and WHO-5/MDI-2 for screening cardiac patients across diagnoses for anxiety and depression in clinical practice.
No takes yet. Share an insight, caveat, or question.
Johnsen et al. (2023) conducted a cross-sectional in ischaemic heart disease, heart failure, heart valve disease, or atrial fibrillation (n=4,346). Combination of WHO-5, ASS-2, and MDI-2 vs. Hospital Anxiety and Depression Scale (HADS) was evaluated on Model fit of the bi-factor IRT models (essential uni-dimensionality). A combination of WHO-5, ASS-2, and MDI-2 measured the same traits as HADS for anxiety and depression, demonstrating appropriate model fit and enabling the use of crosswalks for clinical screening.
Synapse has enriched 10 related papers. Consider them for comparative context: